Axsome Headed to FDA after Phase III Alzheimer's Agitation Win

A Phase III trial of Axsome Therapeutics’ oral N-methyl D-aspartate (NMDA) receptor antagonist hit both primary and secondary endpoints in patients with Alzheimer’s disease agitation, a condition for which there is currently no approved treatment.